Maraviroc: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) recommended or restricted maraviroc, while CIPM (Spain) and SMC (Scotland) did not recommend it.
The file has been open for more than a decade: 17 years separate the first record, 7 Apr 2008 at SMC (Scotland), from the most recent, 24 Apr 2025 at CIPM (Spain).
AWMSG (Wales) changed its position: recommended on 11 Jun 2009, not recommended by 26 Oct 2017.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for maraviroc, 1 submission was never made — an outcome set by the company rather than the assessor.
Against its own class, maraviroc is an outlier: 38% of its decisive outcomes were positive, where molecules sharing ATC class J05A average 87%.
5 distinct indication wordings are recorded for maraviroc by the agencies that label one in English (AWMSG and SMC).
SMC (Scotland) was first to assess maraviroc, on 7 Apr 2008; CIPM (Spain) did not open a file until 26 Feb 2025 — an unusually long tail of 16.8 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 5 years in total.
4 of the 4 agencies here assessed maraviroc more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed maraviroc.
The full ledger for maraviroc reads 5 not recommended, 3 recommended, 2 other and 1 non-submission.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 24 Apr 2025 | Indicación terapéutica autorizada: En combinación con otros medicamentos antirretrovirales, está indicado para el tratam… | not financed by the SNS · art. 92 d | source |
| CIPM (Spain) | 26 Feb 2025 | Indicación terapéutica autorizada: En combinación con otros medicamentos antirretrovirales, está indicado para el tratam… | not financed by the SNS · art. 92 d | source |
| HAS (France) | 25 Jul 2018 | Listing renewal (Transparency Committee) | SMR substantial | source |
| AWMSG (Wales) | 26 Oct 2017 | In combination with other antiretroviral medicinal products for treatment-experienced adolescents and children of 2 year… | not endorsed (non-submission) | source |
| SMC (Scotland) | 9 Oct 2017 | In combination with other antiretroviral medicinal products for treatment-experienced adolescents and children of 2 years and older and weighing at least 10kg infected wi… | not recommended | source |
6 further decisions for maraviroc, across 3 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
- darunavir — same ATC class J05A — Antivirals
Coverage: 11 decisions for maraviroc from 4 agencies, 2008 to 2025. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.